Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice

Aldo P. Maggioni, Cristina Opasich, Inder Anand, Simona Barlera, Emanuele Carbonieri, Lucio Gonzini, Luigi Tavazzi, Roberto Latini, Jay Cohn

Research output: Contribution to journalArticle

Abstract

Background: Aims of the present study were (1) to confirm the prognostic role of anemia in patients with heart failure (HF) and (2) to analyze this aspect in relatively unselected patients with HF monitored prospectively in a community setting (IN-CHF), and in patients selected for enrolment into the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: In both Val-HeFT and IN-CHF Registry, anemia was defined as a hemoglobin (Hb) level ≤11 g/dL in women and ≤12 g/dL in men. Of the 2411 patients of the IN-CHF Registry, 15.5% had anemia, whereas in the 5010 patients of the Val-HeFT trial, the prevalence was 9.9%. In the IN-CHF registry, 1-year all-cause mortality was significantly higher in anemic patients (25.9%) than in patients without anemia (13.2%) (P <.0001). The association of anemia with mortality was confirmed by the multivariable analysis (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.20-1.97). The risk of death decreased by 9.7% for each gram of Hb. The Val-HeFT trial showed an all-cause mortality rate for anemic patients of 29.6% over a mean follow-up period of 22.4 months versus 18.5% (P <.0001) in patients without anemia. After adjustment, anemia retained its negative independent prognostic role (HR 1.26, 95% CI 1.04-1.52). When Hb was considered as a continuous variable, the risk of death decreased by 7.8% for each gram of Hb. Conclusions: Anemia was confirmed to be an independent negative prognostic factor in patients with HF. This finding is consistent in 2 different clinical contexts, a controlled trial and a registry in clinical practice, in which patient characteristics and outcome are largely different.

Original languageEnglish
Pages (from-to)91-98
Number of pages8
JournalJournal of Cardiac Failure
Volume11
Issue number2
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Controlled Clinical Trials
Anemia
Valsartan
Heart Failure
Registries
Hemoglobins
Mortality
Confidence Intervals

Keywords

  • Anemia
  • Epidemiology
  • Heart failure
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Anemia in patients with heart failure : Prevalence and prognostic role in a controlled trial and in clinical practice. / Maggioni, Aldo P.; Opasich, Cristina; Anand, Inder; Barlera, Simona; Carbonieri, Emanuele; Gonzini, Lucio; Tavazzi, Luigi; Latini, Roberto; Cohn, Jay.

In: Journal of Cardiac Failure, Vol. 11, No. 2, 03.2005, p. 91-98.

Research output: Contribution to journalArticle

Maggioni, AP, Opasich, C, Anand, I, Barlera, S, Carbonieri, E, Gonzini, L, Tavazzi, L, Latini, R & Cohn, J 2005, 'Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice', Journal of Cardiac Failure, vol. 11, no. 2, pp. 91-98. https://doi.org/10.1016/j.cardfail.2004.05.004
Maggioni, Aldo P. ; Opasich, Cristina ; Anand, Inder ; Barlera, Simona ; Carbonieri, Emanuele ; Gonzini, Lucio ; Tavazzi, Luigi ; Latini, Roberto ; Cohn, Jay. / Anemia in patients with heart failure : Prevalence and prognostic role in a controlled trial and in clinical practice. In: Journal of Cardiac Failure. 2005 ; Vol. 11, No. 2. pp. 91-98.
@article{b5481c2d9f4c444e902ea4dd64f7e85a,
title = "Anemia in patients with heart failure: Prevalence and prognostic role in a controlled trial and in clinical practice",
abstract = "Background: Aims of the present study were (1) to confirm the prognostic role of anemia in patients with heart failure (HF) and (2) to analyze this aspect in relatively unselected patients with HF monitored prospectively in a community setting (IN-CHF), and in patients selected for enrolment into the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: In both Val-HeFT and IN-CHF Registry, anemia was defined as a hemoglobin (Hb) level ≤11 g/dL in women and ≤12 g/dL in men. Of the 2411 patients of the IN-CHF Registry, 15.5{\%} had anemia, whereas in the 5010 patients of the Val-HeFT trial, the prevalence was 9.9{\%}. In the IN-CHF registry, 1-year all-cause mortality was significantly higher in anemic patients (25.9{\%}) than in patients without anemia (13.2{\%}) (P <.0001). The association of anemia with mortality was confirmed by the multivariable analysis (hazard ratio [HR] 1.54, 95{\%} confidence interval [CI] 1.20-1.97). The risk of death decreased by 9.7{\%} for each gram of Hb. The Val-HeFT trial showed an all-cause mortality rate for anemic patients of 29.6{\%} over a mean follow-up period of 22.4 months versus 18.5{\%} (P <.0001) in patients without anemia. After adjustment, anemia retained its negative independent prognostic role (HR 1.26, 95{\%} CI 1.04-1.52). When Hb was considered as a continuous variable, the risk of death decreased by 7.8{\%} for each gram of Hb. Conclusions: Anemia was confirmed to be an independent negative prognostic factor in patients with HF. This finding is consistent in 2 different clinical contexts, a controlled trial and a registry in clinical practice, in which patient characteristics and outcome are largely different.",
keywords = "Anemia, Epidemiology, Heart failure, Prognosis",
author = "Maggioni, {Aldo P.} and Cristina Opasich and Inder Anand and Simona Barlera and Emanuele Carbonieri and Lucio Gonzini and Luigi Tavazzi and Roberto Latini and Jay Cohn",
year = "2005",
month = "3",
doi = "10.1016/j.cardfail.2004.05.004",
language = "English",
volume = "11",
pages = "91--98",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Anemia in patients with heart failure

T2 - Prevalence and prognostic role in a controlled trial and in clinical practice

AU - Maggioni, Aldo P.

AU - Opasich, Cristina

AU - Anand, Inder

AU - Barlera, Simona

AU - Carbonieri, Emanuele

AU - Gonzini, Lucio

AU - Tavazzi, Luigi

AU - Latini, Roberto

AU - Cohn, Jay

PY - 2005/3

Y1 - 2005/3

N2 - Background: Aims of the present study were (1) to confirm the prognostic role of anemia in patients with heart failure (HF) and (2) to analyze this aspect in relatively unselected patients with HF monitored prospectively in a community setting (IN-CHF), and in patients selected for enrolment into the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: In both Val-HeFT and IN-CHF Registry, anemia was defined as a hemoglobin (Hb) level ≤11 g/dL in women and ≤12 g/dL in men. Of the 2411 patients of the IN-CHF Registry, 15.5% had anemia, whereas in the 5010 patients of the Val-HeFT trial, the prevalence was 9.9%. In the IN-CHF registry, 1-year all-cause mortality was significantly higher in anemic patients (25.9%) than in patients without anemia (13.2%) (P <.0001). The association of anemia with mortality was confirmed by the multivariable analysis (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.20-1.97). The risk of death decreased by 9.7% for each gram of Hb. The Val-HeFT trial showed an all-cause mortality rate for anemic patients of 29.6% over a mean follow-up period of 22.4 months versus 18.5% (P <.0001) in patients without anemia. After adjustment, anemia retained its negative independent prognostic role (HR 1.26, 95% CI 1.04-1.52). When Hb was considered as a continuous variable, the risk of death decreased by 7.8% for each gram of Hb. Conclusions: Anemia was confirmed to be an independent negative prognostic factor in patients with HF. This finding is consistent in 2 different clinical contexts, a controlled trial and a registry in clinical practice, in which patient characteristics and outcome are largely different.

AB - Background: Aims of the present study were (1) to confirm the prognostic role of anemia in patients with heart failure (HF) and (2) to analyze this aspect in relatively unselected patients with HF monitored prospectively in a community setting (IN-CHF), and in patients selected for enrolment into the Valsartan Heart Failure Trial (Val-HeFT). Methods and Results: In both Val-HeFT and IN-CHF Registry, anemia was defined as a hemoglobin (Hb) level ≤11 g/dL in women and ≤12 g/dL in men. Of the 2411 patients of the IN-CHF Registry, 15.5% had anemia, whereas in the 5010 patients of the Val-HeFT trial, the prevalence was 9.9%. In the IN-CHF registry, 1-year all-cause mortality was significantly higher in anemic patients (25.9%) than in patients without anemia (13.2%) (P <.0001). The association of anemia with mortality was confirmed by the multivariable analysis (hazard ratio [HR] 1.54, 95% confidence interval [CI] 1.20-1.97). The risk of death decreased by 9.7% for each gram of Hb. The Val-HeFT trial showed an all-cause mortality rate for anemic patients of 29.6% over a mean follow-up period of 22.4 months versus 18.5% (P <.0001) in patients without anemia. After adjustment, anemia retained its negative independent prognostic role (HR 1.26, 95% CI 1.04-1.52). When Hb was considered as a continuous variable, the risk of death decreased by 7.8% for each gram of Hb. Conclusions: Anemia was confirmed to be an independent negative prognostic factor in patients with HF. This finding is consistent in 2 different clinical contexts, a controlled trial and a registry in clinical practice, in which patient characteristics and outcome are largely different.

KW - Anemia

KW - Epidemiology

KW - Heart failure

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=13944270337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13944270337&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2004.05.004

DO - 10.1016/j.cardfail.2004.05.004

M3 - Article

C2 - 15732027

AN - SCOPUS:13944270337

VL - 11

SP - 91

EP - 98

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 2

ER -